|
Orthologous residues
|
|
PTP1B (human): S50‑p, PTP1B (mouse): S50‑p, PTP1B (chicken): S50‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling, mutation of modification site
|
|
Disease tissue studied:
liver cancer
|
|
Relevant cell lines - cell types - tissues:
3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout], COS (fibroblast), HepG2 (hepatic)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human, monkey, mouse
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
Akt1 (human)
|
modification site within consensus motif, pharmacological activator of upstream enzyme, transfection of dominant-negative enzyme, transfection of constitutively active enzyme, pharmacological inhibitor of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
insulin
|
|
|
|
increase
|
|
|
wortmannin
|
insulin
|
|
|
inhibit treatment-induced increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
enzymatic activity, inhibited, molecular association, regulation
|
|
Modification regulates interactions with:
|
|
Interacting molecule
|
Interacting domains
|
Effect
|
Consequences (function)
|
Consequences (process)
|
Detection assays
|
|
InsR (human)
|
|
Disrupts
|
|
|
co-immunoprecipitation
|
|
